MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-27-2026
Fennec Pharmaceuticals Retained Earnings 2011-2026 | FENC
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Fennec Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -229 M | -220 M | -219 M | -203 M | -179 M | - | -144 M | -131 M | -121 M | -114 M | -112 M | -111 M | -109 M | -111 M | -105 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -105 M | -229 M | -151 M |
Quarterly Retained Earnings Fennec Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -225 M | -224 M | -221 M | -220 M | -218 M | -212 M | -206 M | -219 M | -217 M | -215 M | -209 M | -203 M | -196 M | -188 M | -183 M | -179 M | -175 M | -171 M | -167 M | -162 M | -162 M | -162 M | -148 M | -144 M | -144 M | -144 M | -144 M | -131 M | -131 M | -131 M | -131 M | -121 M | -121 M | -121 M | -121 M | -114 M | -114 M | -114 M | -114 M | -112 M | -112 M | -112 M | -112 M | -111 M | -111 M | -111 M | -111 M | -109 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -109 M | -225 M | -157 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Anika Therapeutics
ANIK
|
128 M | $ 14.93 | 0.88 % | $ 219 M |  USA |
 |
Aptorum Group Limited
APM
|
-72.4 M | $ 0.93 | 0.51 % | $ 5.07 M |  China |
 |
Aquestive Therapeutics
AQST
|
-447 M | $ 4.14 | 0.36 % | $ 443 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-515 M | $ 8.39 | 4.5 % | $ 230 M |  Israel |
 |
Ardelyx
ARDX
|
-947 M | $ 6.06 | 1.94 % | $ 1.46 B | USA |
 |
argenx SE
ARGX
|
-861 M | $ 749.68 | 0.44 % | $ 25 B |  Niderland |
 |
Arcutis Biotherapeutics
ARQT
|
-1.14 B | $ 23.93 | 1.27 % | $ 3.04 B | USA |
 |
Arvinas
ARVN
|
-1.61 B | $ 11.36 | 4.7 % | $ 805 M | USA |
 |
I-Mab
IMAB
|
-8.33 B | - | - | $ 866 M | China |
 |
Arrowhead Pharmaceuticals
ARWR
|
-1.63 B | $ 61.99 | 1.57 % | $ 8.29 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-405 M | - | 2.54 % | $ 160 B |  France |
 |
Assembly Biosciences
ASMB
|
-832 M | $ 29.09 | 0.28 % | $ 326 M | USA |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M | France |
 |
Actinium Pharmaceuticals
ATNM
|
-410 M | $ 1.13 | 15.26 % | $ 35.3 M | USA |
 |
Atossa Therapeutics
ATOS
|
-247 M | $ 5.19 | -3.36 % | $ 44.7 M | USA |
 |
Atara Biotherapeutics
ATRA
|
-2.02 B | $ 5.0 | 0.2 % | $ 62.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
-649 M | $ 16.05 | 2.79 % | $ 2.16 B |  Canada |
 |
Autolus Therapeutics plc
AUTL
|
-1.39 B | $ 1.41 | -0.35 % | $ 375 M | Britain |
 |
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K | USA |
 |
Axon Enterprise
AXON
|
812 M | $ 411.97 | -0.2 % | $ 31.2 B | USA |
 |
Aytu BioScience
AYTU
|
-334 M | $ 2.65 | -1.12 % | $ 16.6 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-1.07 B | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
-197 M | - | -9.65 % | $ 45.9 M | USA |
 |
Applied Molecular Transport
AMTI
|
-366 M | - | - | $ 10.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
-335 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-63.5 M | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
-268 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-1.13 B | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-308 M | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
-826 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-168 M | - | 0.23 % | $ 488 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
BioCardia
BCDA
|
-168 M | $ 1.18 | -1.67 % | $ 7.87 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
-1.77 B | $ 9.59 | 6.26 % | $ 1.98 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-246 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-224 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-401 M | - | 10.36 % | $ 9.8 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
-382 M | $ 3.05 | 1.51 % | $ 260 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-2.59 B | $ 9.46 | -3.47 % | $ 612 M | USA |
 |
BioVie
BIVI
|
-352 M | $ 1.46 | 2.81 % | $ 2.16 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-278 M | $ 2.32 | 4.98 % | $ 908 M | Israel |
 |
BioMarin Pharmaceutical
BMRN
|
154 M | $ 56.04 | 0.96 % | $ 10.7 B | USA |
 |
BioNTech SE
BNTX
|
-410 M | $ 91.64 | 0.5 % | $ 27.2 B | Germany |
 |
Aravive
ARAV
|
-616 M | - | -13.39 % | $ 1.45 M | USA |
 |
BioXcel Therapeutics
BTAI
|
-720 M | $ 1.18 | -0.42 % | $ 14.4 M | USA |